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Abstract
Background: A potential strategy for treatment of sickle cell disease (SCD) and b-thalassemia in adults is
reactivation of the ε- and g-globin genes in the adult. We aimed to identify trans-activators of ε- and g-globin
expression and provide new candidate targets for effective treatment of sickle cell disease (SCD) and b-thalassemia
through activation of ε- and g-globin genes in adults.
Results: We identified a CTD small phosphatase like 2 (CTDSPL2) gene that had higher transcription levels in
umbilical cord blood (UCB) than in adult bone marrow (BM). Also, transcription of the CTDSPL2 gene increased
significantly during erythroid differentiation. Further, we found that overexpression of CTDSPL2 could obviously
improve the expression of ε- and g-globin genes in K562 cells. Meanwhile, the repression of CTDSPL2 by RNA
interference decreased expression of ε- and g-globin genes but did not inhibit the increase of globin gene
expression during K562 erythroid differentiation. In addition, the enforced expression of CTDSPL2 gene mediated
by lentiviruses could also increase ε- and g-globin gene expression during erythroid differentiation of CD34+ cells
derived from UCB.
Conclusion: CTDSPL2 gene can obviously improve the expression of ε- and g-globin genes in K562 cells and
CD34+ cells derived from UCB. Our study provides a new candidate target for effective treatment of SCD and
b-thalassemia.
Background
During development the expression of human b-like glo-
bin genes displays two switches: the embryonic (ε-) to fetal
(Gg-a n dA g-) globin switch, coinciding with the transition
from embryonic (yolk sac) to definitive (fetal liver) haema-
topoiesis, and the fetal to adult (b-) globin switch, occur-
ring near the parturient period with the establishment of
bone marrow as the main site of hematopoiesis [1,2]. It
has been shown that fetal hemoglobin (HbF, a2g2) expres-
sion can be reactivated during adult erythropoiesis [3].
The increased production of fetal hemoglobin could ame-
liorate the clinical severity of sickle cell anemia (SCD) and
b-thalassemia [3]. Therefore, attempts are underway to
screen for pharmaceuticals that reactivate g-globin pro-
duction in adults. Hydroxyurea and sodium butyrate deri-
vatives have been already been examined and used for
treatment of b-hemoglobinopathies [4-8]. While these
therapies are effective for treating SCD and b-thalassemia,
they also have adverse effects such as suppression of cell
growth and bad effects in long-term treatment [9,10].
An alternative treatment strategy is to increase g-globin
expression by controlling potential transcription factors
that specifically activate g-globin expression in the fetus or
result in g-globin gene silencing in the adult. To identify
genes encoding such factors, we analyzed differential
expression of mRNA in erythroid induction cultures of
CD34+ hematopoietic progenitor cells derived from nor-
mal adult bone marrow (BM) and umbilical cord blood
(UCB). One of the differentially expressed genes was
further examined for effects on globin gene expression.
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(CTDSPL2) gene were higher in UCB than in healthy
adult BM. CTD phosphatase dephosphorylates the CTD
tail of the largest subnit of RNA polymerase II (RNAPII).
In vivo, the C-terminal domain (CTD) of the largest subu-
nit of RNA polymerase II is either phosphorylated or
dephosphorylated. Dynamic, site-specific phosphorylation/
dephosphorylation of the CTD occurs during the tran-
scription cycle [11]. Recent observations indicate that
CTD phosphorylation plays a major role in orchestrating
interaction of the CTD with mRNA processing factors
involved in capping, splicing and polyadenylation. Several
kinases modify the CTD phosphorylation state. However,
only a few mammalian CTD phosphatases have been iden-
tified. FCP1, the first characterized CTD phosphatase, con-
tains a BRCT domain required for RNAPII interaction and
CTD dephosphorylation [12]. SCP1 and UBLCP1 contain
phosphatase domains similart oF C P 1 ,a n da l s od e p h o -
sphorylate Ser-2 and Ser-5 of phosphorylated CTD
in vitro [13]. The CTDSPL2 gene product contains a
CTD phosphatase catalytic domain (CPDc) and the gene
is 47% homologous to FCP1. The function of this gene is
not known although it has been shown to dephosphorylate
phophoserine-5 and phosphoserine-2 within GST-CTDo
in vitro [14].
In this study, we show that overexpression of CTDSPL2
significantly increased the ε-a n dg- globin gene expression
in K562 cells and CD34+ cells derived from UCB while
have faint effect on ζ-, a-a n db-globin gene.
Results
Expression pattern of CTDSPL2 in BM and UCB and
during erythroid differentiation
We analyzed differential expression of genes in CD34+
erythroid induction cell cultures derived from normal
adult BM and UCB by differential display reverse tran-
scription PCR (DDRT-PCR). CTDSPL2 had higher
expression levels in erythroid cultures derived from
UCB than from healthy adult BM. Differential expres-
sion of CTDSPL2 was also detected by real-time PCR.
Expression levels of CTDSPL2 mRNA in UCB erythroid
cultures were 2.6 times greater than in healthy adult
BM erythroid cultures (Fig. 1A).
The level of CTDSPL2 mRNA during Epo-induced ery-
throid differentiation in UCB-derived CD34+ HPCs was
measured by real-time PCR. CTDSPL2 mRNA levels
increased during erythroid differentiation (Fig. 1B). The
mRNA expression of CTDSPL2 in hemin- and butyrate-
induced K562 cells was measured by Northern blot analy-
sis (Fig. 1C). CTDSPL2 mRNA levels were also measured
by real-time PCR at different time points during hemin-
induction of K562 cells (Fig. 1D). Levels of CTDSPL2
mRNA increased in hemin- and butyrate-induced K562
cells. CTDSPL2’s increase was more evident during
hemin-induced K562 cell differentiation.
Overexpression of CTDSPL2 increases hemoglobin-
containing cells during erythroid differentiation of K562 cells
We collected five stable pools of K562 cells transfected
with pc3.1-CTDSPL2 (each pool was originally from a
collection of 20 to 30 individual clones). Real-time PCR
analysis revealed that transcription of the CTDSPL2
gene in these five transfectant pools was on average 2
times greater than in the K562/pc3.1 transfectant pools
and in un-transfected K562 cells (Fig. 2A). The Western
blot analysis also revealed an obvious increase of
CTDSPL2 protein in the K562/pc3.1-CTDSPL2 transfec-
tant pools (Fig. 2B).
Erythroid differentiation was induced in stable K562
transfectants and un-transfected K562 cells by hemin.
The cells were collected and analyzed by benzidine
staining 0, 12, 24, 36, 48, 60, 72 h after hemin induction
(Fig. 2C). Among the five pc3.1-CTDSPL2 transfectant
pools, there were four (A, C, D and E) with especially
high benzidine-positive cell levels. Before erythroid dif-
ferentiation, 17-22% of the cells were benzidine-positive,
which is equivalent to that in control cells 60 h after
being induced by hemin. For these four transfectant
pools, benzidine-positive cells were 75-80% at 72 h after
hemin induction, significantly greater than for control
cells. The percentage of benzidine-positive cells in the
transfectant pool B was also higher than control cells
during erythroid differentiation.
Overexpression of CTDSPL2 increases ε- and g- globin
gene expression in K562 cells
The transcription of a number of globin genes (includ-
ing a-, ζ-, ε-, g-a n db-globin genes) was analyzed by
real-time PCR in the K562 transfectants. Overexpression
of the CTDSPL2 gene significantly increased transcrip-
tion of ε-a n dg-globin genes in K562 cells but had little
effect on a-, ζ-a n db-globin gene transcription. Tran-
scription of ε-a n dg-globin genes in the stable K562
pc3.1-CTDSPL2 transfectant pools was 12 and 6 times
greater respectively than K562/pc3.1 transfectant pools
and untransfected K562 cells (Fig. 2D). The improve-
ment on a-, ζ-a n db-globin gene expression was weak
relative to the effects on ε- and g-globin genes.
Erythroid differentiation in the transfected cells was
induced by hemin. Cells were collected 72 h after hemin
induction. Overexpression of CTDSPL2 increased
expression of ε-a n dg-globin genes after erythroid dif-
ferentiation of K562 cells (Fig. 2E). The expression of
ε- and g-globin gene was 7 and 3.5 times greater respec-
tively in the K562 transfectants overexpressing
CTDSPL2 than in K562/pc3.1 control cells and K562
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CTDSPL2 overexpression on globin gene transcription
were less before erythroid differentiation than after
differentiation.
Transcription of a-, ε-, g-a n db-globin genes in the
transfected K562 cells before and after erythroid differen-
tiation was also analyzed by RNase protective assay. Before
hemin induction (Fig. 3A), ε-globin mRNA levels in the
stable K562/pc3.1-CTDSPL2 transfectants were signifi-
cantly higher than in control cells. g-globin mRNA levels
in K562/pc3.1-CTDSPL2 transfectants were also greater
relative to control cells which have high g-globin mRNA
levels. a-globin mRNA in K562/pc3.1-CTDSPL2 transfec-
tants was greater than in control cells but a-globin mRNA
was still at a low level. b-globin mRNA was undetected in
all samples.
After hemin induction, transcription of all globin
genes excluding b-globin increased in all cells (Fig. 3B).
Levels of ε-a n dg- g l o b i nm R N Ai nt h es t a b l eK 5 6 2 /
pc3.1-CTDSPL2 transfectants was higher than in control
cells. Transcription of the a- g l o b i ng e n ei nt h es t a b l e
K562/pc3.1-CTDSPL2 transfectants was also higher than
in the control cells but the a-globin mRNA was still at
a low level. b-globin mRNA was still undetected after
erythroid differentiation.
Repression of CTDSPL2 gene decreases the number of
hemoglobin-containing K562 cells
Recombinant RNAi plasmids (RNAiA, RNAiB) and the
pSilencer2.1-U6-Neo control vector were co-transfected
into Hela cells with the CTDSPL2-GFP fusion expression
plasmid. CTDSPL2-GFP expression was observed to
Figure 1 CTDSPL2 mRNA levels in erythroid cultures from BM and UCB and during erythroid differentiation of K562 cells and CD34+
HPCs. (A) Differential expression of CTDSPL2 in erythroid cultures from healthy adult bone marrow (BM) and umbilical cord blood (UCB) as
measured by DDRT-PCR (top) and real-time PCR (bottom). (B) CTDSPL2 mRNA expression at different days during EPO-induced CD34+ cell
erythroid differentiation as determined by real-time PCR. (C) Northern blot analysis of CTDSPL2 mRNA expression in K562 cells 48 h after
treatment with butyrate and hemin. (D) Real-time PCR analysis of CTDSPL2 mRNA expression at different time points during hemin-induced
K562 cell erythroid differentiation.
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Page 3 of 11Figure 2 Overexpression of CTDSPL2 increases ε-a n dg- globin gene expression in K562 cells. (A) Overexpression of CTDSPL2 mRNA in
stable K562/pc3.1-CTDSPL2 transfectant pools as analyzed by real-time PCR. (B) Overexpression of CTDSPL2 protein in stable K562/pc3.1-
CTDSPL2 transfectant pools as analyzed by Western blot. (C) Hemoglobin-containing cells were detected by benzidine staining during hemin-
induced erythroid differentiation of K562 cells. The data were obtained from three independent experiments and the error bars represent
standard deviation. (D) Real-time PCR analysis of a-, ζ-, ε-, g- and b-globin genes mRNA expression in K562 cells, K562/pc3.1 transfectants and
K562/pc3.1-CTDSPL2 transfectants. (E) Real-time PCR analysis of a-, ζ-, ε-, g- and b-globin mRNA expression in K562 cells, stable K562/pc3.1
transfectants and K562/pc3.1-CTDSPL2 transfectants 72 h after treatment with hemin. K562 and pc3.1 represent K562 cells and stable K562/pc3.1
transfectant pool respectively. A, B, C, D and E represent the five stable K562/pc3.1-CTDSPL2 transfectant pools respectively.
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CTDSPL2-GFP was strongly repressed in Hela cells trans-
fected with RNAiA and RNAiB compared to cells trans-
fected with pSilencer2.1-U6-Neo (Fig. 4A). Both the
intensity of green fluorescence in each cell and the num-
ber of cells that express green fluorescent protein
decreased. RNAiB transfection resulted in greater repres-
sion of fluorescence. These results indicate that these two
RNAi plasmids repress expression of CTDSPL2-GFP
effectively. As the repression efficiency of RNAiB was
much greater, RNAiB (1057 AAGGTGTATGCAGA-
CAAGTTA) was used in further experiments.
RNAiB was subcloned into the pLVTHM vector and
high titer lentiviruses were acquired. By lentivirus infec-
tion, we got stable K562/CTDSPL2RNAi transfectant
pool. CTDSPL2 mRNA level measured by real-time
PCR in the stable K562/CTDSPL2 RNAi transfectant
pool was 40% of that in the control cells (Fig. 4B). An
increased CTDSPL2 mRNA level in the stable K562/
CTDSPL2 RNAi transfectant pool was detected after
hemin induction 72 h but it was only 55% of that in the
hemin-induced control cells.
Erythroid differentiation was induced in stable K562/
CTDSPL2 RNAi transfectant pool and control cells by
hemin and the cells were collected and analyzed by benzi-
dine staining at different time points after hemin induction
(Fig. 4C). Benzidine-positive cell percentages in stable
K562/CTDSPL2 RNAi transfectant pool were lower than
in control cells at the early erythroid differentiation stage.
However, this phenomenon disappeared after hemin
induction 48 h. The phenomena suggested that the repres-
sion of CTDSPL2 gene in K562 cells could decrease the
hemoglobin-containing cells but could not inhibit the
increase of hemoglobin-containing cells during hemin-
induced K562 cells erythroid differentiation.
Repression of CTDSPL2 gene in K562 cells can decrease
the expression of ε- and g-globin gene
The transcription of a-, ζ-, ε-, g-a n db-globin genes in
the stable K562/CTDSPL2 RNAi transfectants and con-
trol cells were analyzed by real-time PCR before and
after erythroid differentiation. Before hemin induction,
ε-a n dg-globin transcription in the K562/CTDSPL2
RNAi transfectants was much less than that in control
cells (Fig. 4D). ε-globin gene transcription was only 25%
of that in control cells while g- globin transcription was
41% of that in control cells. b-, ζ-a n db-globin gene
transcription was also less than that in control cells but
the difference was not significant. 72 h after hemin
induction, no significant difference of any globin gene
transcription was found between the stable K562/
CTDSPL2 RNAi transfectants and control cells (Fig. 4E).
CTDSPL2 overexpression increases ε- and g- globin gene
expression in CD34+ HPCs derived from UCB
Two high titer lentiviruses that carry pWPXL-CTDSPL2
and pLVTHM-CTDSPL2 RNAi were obtained. CD34+
HPCs from normal UCB were purified and were infected
Figure 3 R N a s ep r o t e c t i v ea s s a yo fa-, ε-, g-a n db-globin gene mRNA expression in K562 cells before and after erythroid
differentiation. (A) Globin gene expression in un-induced K562 cells. (B) Globin gene expression in K562 cells 72 h after treatment with hemin.
K562 and pc3.1 represent K562 cells and stable K562/pc3.1 transfectant pool respectively. A, B, C, D and E represent the five stable K562/pc3.1-
CTDSPL2 transfectant pools respectively.
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transduction efficiency of the CD34+ cells was about
70-80% through observing GFP expression. CTDSPL2
mRNA was detected by real-time PCR. CTDSPL2 mRNA
levels in CD34+ cells infected by lentiviruses carrying
pWPXL-CTDSPL2 were 3.5 times greater than that
in control cells (Fig. 5A). CTDSPL2 mRNA levels in
CD34+ cells infected by lentiviruses carrying pLVTHM-
CTDSPL2 RNAi were 55% of that in control cells
(Fig. 5A).
Globin mRNA levels in the lentivirus-infected CD34+
cells were analyzed by real-time PCR before and after
Epo-induced erythroid differentiation. There were
mainly the a-a n dg-globin gene expression in UCB
derived CD34+ cells (Fig. 5B). a-a n dg-globin mRNA
levels were 40 times greater after Epo-induced erythroid
differentiation (Fig. 5C).
Overexpression of CTDSPL2 gene in CD34+ HPCs
increased transcription of all globin genes (Fig. 5D).
ε-globin mRNA in CD34+ HPCs overexpressing
CTDSPL2 was 2.5 times greater than in control cells.
Repression of the CTDSPL2 gene in CD34+ HPCs
decreased transcription of the ε-globin gene but had little
effect on other globin genes. ε-globin gene expression in
CD34+ HPCs with repressed CTDSPL2 was only 22% of
that in control cells.
Transcription of a number of globin genes in the lenti-
virus-infected CD34+ cells was measured 7 days after
induction by Epo (Fig. 5E). Increases in ε-globin gene
transcription in Epo-induced CD34+ cells were much
stronger than in un-induced CD34+ cells. ε-globin gene
transcription in CD34+ HPCs overexpressing CTDSPL2
was 5.8 times greater than in control cells. Overexpres-
sion of the CTDSPL2 gene also increased a- and g-globin
Figure 4 Effects of CTDSPL2 repression on globin gene expression in K562 cells. (A) Fluorescent microscopy indicating CTDSPL2-GFP
expression showing CTDSPL2 repression by two siRNAs in Hela cells. (B) Real-time PCR analysis of CTDSPL2 mRNA expression in stable K562/
CTDSPL2 RNAi transfectants. (C) Hemoglobin-containing cells were detected by benzidine staining during hemin-induced erythroid
differentiation of the above K562 cells. The data were obtained from three independent experiments and the error bars represent standard
deviation. (D) Real-time PCR analysis of a-, ζ-, ε-, g- and b-globin mRNA expression in the stable K562/CTDSPL2RNAi transfectants carrying the
recombinant pLVTHM CTDSPL2RNAi (RNAi) and the stable K562/CTDSPL2 transfectants carrying the blank pLVTHM (Control). (E) Real-time PCR
analysis of a-, ζ-, ε-, g- and b-globin mRNA expression 72 h after hemin treatment in stable K562/CTDSPL2RNAi transfectants and the stable
K562/CTDSPL2 transfectants.
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Decreases of globin gene transcription in CD34+ cells
with repressed CTDSPL2 were no longer observed after
erythroid differentiation.
Discussion
By differential display analysis, we found that the tran-
scription of the CTDSPL2 gene in UCB erythroid cultures
was greater than in adult BM erythroid cultures. Mean-
while, g-globin gene developmentally expressed mainly in
UCB and little in adult BM [15]. Furthermore, we mea-
sured transcription levels of CTDSPL2 during hemin-
induced erythroid differentiation of K562 cells and Epo-
induced erythroid differentiation of CD34+ HPCs and
found that its expression increased significantly during
erythroid differentiation. g-globin gene transcription also
increased significantly during hemin-induced erythroid
differentiation in K562 cells and Epo-induced erythroid
differentiation in CD34+ HPCs [16,17]. Based on this
evidence, we hypothesized that CTDSPL2 plays a role in
g-globin gene activation.
CTD phosphatases can dephosphorylate the CTD tail
of the largest subnit of RNAPII and play a major role in
mRNA processing. Only a few mammalian CTD phos-
phatases have been identified [12]. CTD small phospha-
tase like 2 (CTDSPL2) contains a CTD phosphatase
catalytic domain (CPDc) and dephosphorylates phopho-
serine-5 and phosphoserine-2 within GST-CTDo
in vitro [14].
The K562 cell line was chosen for this study as it is
commonly used to study globin gene regulation [18,19].
We prepared five stable K562/pc3.1-CTDSPL2 transfec-
tant pools. Benzidine staining showed that overexpres-
sion of the CTDSPL2 gene increased the number of
hemoglobin-containing cells during K562 erythroid dif-
ferentiation. To determine which globin genes are
affected, a number of globin genes (including a-, ζ-, ε-,
g- and b-globin genes) were analyzed. The results showed
Figure 5 Effects of overexpression and repression of CTDSPL2 on globin gene expression in CD34+ HPCs. (A) Detection of
overexpression and repression of CTDSPL2 gene in CD34+ cells by real-time PCR. (B) Relative expression of globin genes in CD34+ cells derived
from UCB. (C) Relative expression of globin genes in CD34+ cells derived from UCB 7 days after Epo-induced erythroid differentiation. (D) Real-
time PCR analysis of globin gene expression in CD34+ cells overexpressing or repressing CTDSPL2. (E) Real-time PCR analysis of globin genes in
EPO-induced CD34+ cells overexpressing or repressing CTDSPL2. C1, Over, C2, RNAi represent the CD34+ cells infected respectively with
lentiviruses carrying the blank pWPXL vector, recombinant pWPXL-CTDSPL2, blank pLVTHM vector and recombinant pLVTHM-CTDSPL2RNAi.
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tion of ε-a n dg-globin genes in K562 cells before and
after erythroid differentiation, while there was only a
small effect on the a-, ζ-a n db-globin genes. Of course,
the random integration into genome and the incomplete
simulation of endogenous gene in overexpression study
may arise some trustless results. But the use of several
stable transfectant pools in this study may partially over-
come this disadvantage.
CTDSPL2 may be specifically recruited into the tran-
scriptional initiation complex at the ε-a n dg-globin
gene promoters through interaction with ε- and g-globin
specific transcription factors. In order to identify candi-
date transcription factors, CTDSPL2-interacting proteins
will need to be determined. Expression of the erythroid
surface marker, CD71, increased to some degree in the
stable K562/pc3.1-CTDSPL2 transfectant pools (data
n o ts h o w n ) .S o ,i ti sa l s op o s s i b l et h a tC T D S P L 2
increased ε-a n dg-globin gene expression by increasing
erythroid differentiation of K562 cells partially.
To determine if CTDSPL2 is necessary for ε- and g-glo-
bin gene expression, we examined the effect of CTDSPL2
repression by RNAi on globin gene expression in K562
cells. Repression of the CTDSPL2 gene decreased the
transcription of the globin genes, especially the ε-globin
gene. However, repression of CTDSPL2 did not inhibit
the increase of globin gene expression during hemin-
induced erythroid differentiation. Therefore, CTDSPL2
can increase ε-a n dg-globin gene expression but it is not
indispensable for increases of ε-a n dg-globin gene
expression during erythroid differentiation. There may be
other genes that can compensate for CTDSPL2 in the
activation of globin gene expression. Alternatively,
CTDSPL2 level is decreased but not eliminated in our
experiments. Transcription of CTDSPL2 in stable K562/
CTDSPL2 RNAi transfectants still increased during ery-
throid differentiation. This may explain why repression
of CTDSPL2 could not inhibit the increase of globin
gene expression during erythroid differentiation.
The effects of CTDSPL2 on globin gene expression
in CD34+ hematopoietic progenitor cells were also exam-
ined. CD34+ hematopoietic progenitor cells were quie-
scent and generally non-dividing. Lentiviruses can
effectively infect quiescent, non-divisive cells and are
widely used in hematopoietic stem cell gene therapy
[20,21]. We achieved overexpression and repression of the
CTDSPL2 gene in CD34+ cells by lentivirus infection. The
effects in lentivirus-infected CD34+ cells were consistent
with those in transfected K562 cells. CTDSPL2 overex-
pression significantly increased ε-globin gene expression
and also increased g-globin gene transcription. The greater
effect of CTDSPL2 on ε-globin gene transcription than
g-globin gene transcription may be partly due to the high
baseline level of g-globin gene transcription in K562 cells
and UCB-derived CD34+ HPCs. In future studies, the
effect of CTDSPL2 on g-globin gene transcription will be
measured in bone marrow-derived CD34+ HPCs in which
there is little g-globin gene expression.
The expression of CTDSPL2 increased significantly
during erythroid differentiation. This suggested that its
expression may be regulated by erythroid differentia-
tion-related factors. The analysis of its promoter and
mechanism of its specific expression is necessary. The
overexpression of CTDSPL2 can specifically increase
epsilon and gamma globin spontaneous expression, but
CTDSPL2 does not contain a DNA binding domain. So
it is impossible for CTDSPL2 to bind to epsilon and
gamma-globin gene promoter directly. And it is possible
that it was recruited to epsilon and gamma-globin gene
promoter by interacting with some important globin
related transcriptional factors such as EKLF, FKLF,
NF-E4, etc. So to find the possible CTDSPL2 interacting
protein through immunoprecipitation or two hybrid
system in mammalian cell is the next step. In addition
to identify the existence of CTDSPL2 in epsilon and
gamma globin gene promoter complex through chroma-
tin immunoprecipitation is also necessary. On the other
hand, it is possible that CTDSPL2 regulate the phos-
phorylation status of the key factors in globin gene
expression. It is reported that SCP1 can dephosphorylate
Ser-2 and Ser-5 of phosphorylated RNA polII CTD
in vitro as FCP1 (the first characterized CTD phospha-
tase) [13]. It is also reported that SCP1-3 can depho-
sphorylate Smad1 C-terminal tail, thereby attenuating
BMP signaling [22]. It also can dephosphorylate the lin-
ker regions of Smad1 and Smad2/3 in vitro [23]. So the
substrate of CTDSPL2 may be various not limited to the
CTD tail of RNA polII.
Conclusions
In conclusion this study showed that CTDSPL2
increases ε-a n dg-globin gene expression in K562 cells
and UCB-derived CD34+ HPCs. Reactivation of the
g-globin gene in the adult has been demonstrated to be
significant for treatment of SCD and b-thalassemia. The
reactivation of the ε-globin gene should also have simi-
lar effects. Thus our study provides a new candidate tar-
get for effective treatment of SCD and b-thalassemia
through activation of ε-a n dg-globin genes in adults.
Further investigation of the mechanism of CTD phos-
phatase in globin gene regulation may open new ways
to regulate gene transcription with CTD phosphatases.
Methods
Cell culture and induction to erythroid differentiation
Informed consent was obtained from all donors. Four
UCB samples (40 to 50 ml each) from normal full-term
deliveries and four BM samples (5 to 10 ml each) from
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anti-coagulant. UCB samples were diluted 1:4 with
phosphate buffered saline (PBS) containing 2 mM
EDTA and 0.5% bovine serum albumin (BSA, Sigma, St.
Louis, MO, USA). To release the cells, BM samples
were diluted with 10 volumes of RPMI 1640 (Gibco,
Invitrogen, Grand Island, NY, USA) containing 0.02%
collagenase B and 100 U/ml DNase (Sigma, St. Louis,
MO, USA) and incubated at room temperature for
45 min. Mononuclear cells (MNCs) were isolated from
the diluted UCB and BM by centrifugation on a gradient
of Ficoll-Hypaque (density 1.077 g/ml, Sigma, St. Louis,
MO, USA) [24]. CD34+ HPCs were purified by positive
selection using Mini-MACS columns according to the
manufacturer’s protocol (Milternyi Biotech, Germany).
The purity of CD34+ cells was then determined (>90%).
Cells were cultured as described previously [25].
Briefly, CD34+ HPCs purified from UCB were cultured
in Iscove’s modified Dulbecco’s medium (IMDM, Gibco,
Invitrogen, Grand Island, NY, USA) containing 1% deio-
nized bovine serum albumin (BSA, fraction V, Sigma,
S t .L o u i s ,M O ,U S A ) ,3 0 %h u m a nc o r ds e r u m( C H S ,
prepared in-house, heterologous), 1 × 10
-5 mol/L 2-mer-
captoethanol (Sigma, St. Louis, MO, USA), 2 × 10
-3
mol/L L-glutamine (Sigma, St. Louis, MO, USA), anti-
biotics (Gibco, Invitrogen, Grand Island, NY, US) and
cytokines (R&D System, Minneapolis, MN. USA) includ-
ing 2 IU/ml Epo, 100 ng/ml SCF and 2 ng/ml IL-3.
CD34+ cells from BM were cultured in the same
serum-containing medium except that 30% CHS was
substituted with 30% human adult AB-type serum
( A H S ,T B D ,T i a n j i n ,PRC h i n a ) .A l lC D 3 4 +c e l l sw e r e
seeded at 1 × 10
5 cells/ml in 6 ml cultures and incu-
bated in a humidified atmosphere at 37°C and 5% CO2
for three weeks.
K562 cells were cultured in DMEM medium (Gibco,
Invitrogen, Grand Island, NY, USA) containing 10% fetal
bovine serum and 2 × 10
-3 mol/L L-glutamine at 37°C
and 5% CO2 and were induced to erythroid differentia-
tion with 40 μmol/L hemin [26]. Cells were counted with
a hemocytometer and hemoglobin-containing erythroid
cells were identified by benzidine staining.
RNA preparation, cDNA synthesis and real-time PCR
Total RNA was extracted from cell samples using TRIzol®
reagent (Invitrogen, Carlsbad, CA, USA) and quantitated
by spectrophotometer. The first-strand of cDNA was
synthesized using Superscript™III reverse transcriptase
(Invitrogen, Carlsbad, CA, USA). Gene-specific primers
were designed using Primer Express (Applied Biosystems,
Foster City, CA) software Version 2.0 (Table 1) [27]. The
mRNA level of target genes in cultured erythroid cells
was quantified by real-time PCR analysis on an ABI
PRISM® 7500 real-time PCR System (Applied Biosystems,
Foster City, CA) with the SYBR® Premix Ex Taq™kit
(Takara, Dalian, P R China). The following PCR cycle
parameters were used: 95°C for 10 s, 40 cycles at 95°C for
5 s, 60°C for 34 s. Each PCR reaction was performed in
triplex tubes with GAPDH as an endogenous control to
standardize the amount of sample cDNA. Data were ana-
lyzed with sequence detection system (SDS) software
(Applied Biosystems, Foster City, CA). The comparative
CT method was used for quantification of the target
genes relative to GAPDH. All real-time PCR analyses
were repeated three times.
Differential display reverse transcription PCR
CD34+ cells derived from UCB and adult BM were col-
lected on day 8 of erythroid culture as our previous results
showed that this is when g-t ob-globin switching occurs
[25]. Total RNA was prepared as above and differential
display reverse transcription-PCR (DDRT-PCR) was per-
formed in combination with 3 anchored primers and 18
arbitrary primers. Briefly, three one-base anchored oligo-
dT primers (A, C, G) were used to synthesize first-strand
cDNA that was then amplified with 18 arbitrary primers
(long primers) in the presence of [a-
32P] dCTP. The fol-
lowing PCR cycle parameters were used: 94°C for 1 min,
40°C for 4 min, 72°C for 1 min; 35 cycles at 94°C for 1
min, 60°C for 2 min, 72°C for 1 min; 72°C for 5 min. Each
PCR reaction was performed in double tubes to confirm
the reproducibility and amplified with GAPDH as an
endogenous control to standardize the amount of sample
cDNA. PCR products were separated on a 6% denaturing
polyacrylamide gel at 85 W on the gel board of sequencing
(Bio-Rad California, USA) according to the manufacturer’s
instructions. The gel was analyzed using the Cyclone Sto-
rage Phosphor System (Packard, USA) and then exposed
for 6 to 12 h at -70°C on X-film (Kodak, P.R China) after
drying at 80°C for 120 min under vacuum (Bio-Rad
California, USA).
Table 1 Oligonucleotide primer sets used in quantitative
real-time PCR experiments
Gene Primer Sequence (5’-3’) Product Size (bp)
g-globin GCAGCTTGTCACAGTGCAGTTC
TGGCAAGAAGGTGCTGACTTC
166
b-globin GTCTACCCTTGGACCCAGAGGTTC
TGAGCCAGGCCATCACTAAAG
131
ε-globin CAGCTGCAATCACTAGCAAGC
AGACGACAGGTTTCCAAAGC
190
a-globin GGTCAACTTCAAGCTCCTAAGC
GCTCACAGAAGCCAGGAACTTG
116
ζ-globin TGAGCGAGCTGCACGCCTAC
GTACTTCTCGGTCAGGACAGA
173
CTDSPL2 TGGAACGTCAGGATCAGATTCTC
GATGGTCTCACTTGAACTGCTTGA
157
GAPDH TCAACGACCACTTTGTCAAGCTCA
GCTGGTGGTCCAGGGGTCTTACT
119
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Cell lysates containing 50 μg protein were loaded on a
12% SDS-PAGE gel and then were transferred to polyvi-
nylidene difluoride membranes (Amersham) using Bio-
Rad’s Transblot for 2 h at 0.2 amp at 4°C. The membrane
was immersed in the blocking buffer (PBS containing 3%
BSA and 0.05% Tween 20) and blocked overnight. Then
the membrane was incubated with the AntiCTDSPL2
(ProTeintech Group, Inc, Chicago, USA) or AntiGAPDH
(Abcam, Cambridge, UK) diluted in blocking buffer for
2 h at room temperature, followed by incubated with the
peroxidase-conjugated affinipure goat anit-mouse IgG
(H+L) (Zhongshang Goldenbridge, Beijing, China)
diluted in the blocking buffer for 2 h at room tempera-
ture. Then chemiluminescence reaction was performed
using ECL Western Blotting Analysis System (Amer-
sham) for 5 min, and then the membranes were exposed
to ECL hyper film (Amersham) for 5 s-15 min.
Overexpression of CTDSPL2 in K562 cells by lipofectamine
transfection
The cDNA fragment including the complete CTDSPL2-
coding sequence was subcloned into Hind III-EcoRV of
the eukaryotic expression vector pcDNA3.1+ (Invitro-
gen, Carlsbad, CA, USA). K562 cells were transfected
with the recombinant plasmid pc3.1-CTDSPL2 and
pc3.1 vector as a control by Lipofectamine 2000 (Invi-
trogen, Carlsbad, CA, USA). Stable K562 transfectants
were selected in the medium containing 500 μg/ml
G418 for 2 weeks. Overexpression of CTDSPL2 in K562
cells was validated by real-time PCR.
Screening for effective RNAi targets of CTDSPL2 gene
The CTDSPL2 open reading frame (ORF) was analyzed
with the Ambion siRNA target finder http://www.ambion.
com. Several possible targets for effective RNAi of
CTDSPL2 gene were selected. DNA sequences that are
siRNAs targets for two sites (326, AAGCTGGTAGTTAT-
GAAATGA; 1057, AAGGTGTATGCAGACAAGTTA)
were inserted into the psilencer2.1-U6-neo vector at the
BamHI and HindIII sites. The coding sequence of
CTDSPL2 gene excluding the stop codon was inserted into
the eukaryotic expression vector pEGFP-N1 in frame of
EGFP and to produce CTDSPL2-GFP fusion protein
expression plasmid. Recombinant RNAi plasmids were
then co-transfected with the CTDSPL2-GFP fusion expres-
sion plasmid into Hela cells. The green fluorescence was
observed to validate CTDSPL2 repression in Hela cells.
Recombinant lentiviruses generation and gene
transduction in CD34+ HPCs
The coding sequence of the CTDSPL2 gene was sub-
cloned into the pWPXL retroviral expression vector at
BamHI and MluI sites joining the 5’end of EGFP to
obtain the recombinant plasmid pWPXL-CTDSPL2. The
effective siRNA sequence was subcloned into the
pLVTHM vector at MluI-ClaI site to get recombinant
plasmid pLVTHM-CTDSPL2 RNAi. The recombinant
plasmids pWPXL-CTDSPL2 or pLVTHM-CTDSPL2
RNAi were co-transfected with packaging plasmid
(pSPAX2) and envelope plasmid (pMD.2G) into 293T
cells by calcium phosphate. The efficiency of transfec-
tion was confirmed by green fluorescence under fluores-
cence microscopy 48 h after transfection. The medium
was collected by centrifugation (3000 rpm, 5 min, room
temperature) 72 h after transfection and then filtered
(0.45 μm). The viruses were concentrated by centrifuga-
tion (26000 rpm, 2 h, 4°C). The supernatant was
discarded and the pellet containing the viruses was re-
suspended in serum-free medium. The virus concentra-
tion was determined by infecting 293T cells followed by
FACS fluorescence analysis.
For gene transduction into CD34+ HPCs, 2 × 10
6 viral
particles were preloaded onto a RetroNectin-coated
plate (Takara, Dalian, China) and incubated at 37°C for
5 h. Just prior to infection, the viral supernatant was dis-
carded and the plate was washed with PBS [28].
Approximately 1 × 10
5 CD34+ cells were then added to
the preloaded viral plate with growth medium, and the
plate was incubated at 37°C. Seventy-two hours after
lentiviruses infection, infected CD34+ cells were induced
to erythroid differentiation by Epo for a week.
RNase protective assay
Human globin mRNAs were analyzed by quantitative
RNase protection assays. Four plasmids containing the
pT7 promoter and a fragment of each of the genes were
used as probe templates. pT7ε,p T 7 g,p T 7 a,p T 7 b-actin
were acquired by cloning EcoRI-KpnI fragments of these
genes downstream from the pT7 promoter in pcDNA3.1
+, linearized with XbaI, giving a protected fragment
derived from exons of their mRNAs of 231 nucleotides,
169 nucleotides, 149 nucleotides, 121 nucleotides
respectively. pT7b came originally from Dr. Li at the
University of Washington [17]. RNA probes, labeled
with a-p32 UTP, were obtained by in vitro transcription
of the plasmids with T7 polymerase and purified accord-
ing to the manufacturer’s instructions (Promega, Madi-
son, WI, USA). Total RNA (4 μg) was hybridized with
3×1 0
5 cpm of each probe at 90°C for 2 min and then
incubated for 12-16 h at 56°C. RNA samples were then
digested with RNase A and T1 for 45 min at 30°C and
incubated with Proteinase K for 15 min at 37°C, using
the ribonuclease protection assay kit (BD Bioscience,
Franklin Lakes, USA). Protected fragments were purified
by extraction with chloroform and precipitation with
ethanol. Then the samples were denatured at 90°C for
3 min before separation on a 4.75% acrylamide/8 M
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California, USA). Gels were analyzed with the Cyclone
Storage Phosphor System (Packard, USA) and then
e x p o s e df o r6t o1 2ha t- 7 0 ° Co nX - f i l m( K o d a k ,P . R
China).
Statistical analysis
Statistical analysis was performed using Student’s paired
t test, p values less than 0.05 were considered to be sig-
nificant. All data were expressed as mean ± S.E, and sta-
tistical analyses were performed by SPSS version 10.0.
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